Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

Zinger Key Points
  • Recent data demonstrated the potential of CD19-directed CAR T therapies in 15 patients with autoimmune diseases.
  • The company shared initial clinical observations from its Phase 1 dose escalation trial of CLN-978 in B cell non-Hodgkin lymphoma.

Cullinan Therapeutics Inc CGEM, formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication

In SLE, the immune system of the body mistakenly attacks healthy tissue.

The company believes that CLN-978 has the potential to be a first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases with a differentiated safety profile​. 

The company plans to submit an investigational new drug application to study CLN-978 in patients with SLE in the third quarter of 2024 and is also planning for future development in other autoimmune diseases. 

Cullinan Therapeutics has discontinued enrollment in its B cell non-Hodgkin lymphoma (B-NHL) study to focus ongoing development on autoimmune indications.

Recent data demonstrated the potential of CD19-directed CAR T therapies in 15 patients with autoimmune diseases.

The company shared initial clinical observations from its Phase 1 dose escalation trial of CLN-978 in B cell non-Hodgkin lymphoma. 

Clinical observations from three patients treated in a Phase 1 dose escalation trial of patients with B-NHL show that CLN-978 was clinically active at the initial starting dose of 30 μg administered subcutaneously once weekly. 

Two of the three patients experienced objective clinical benefit, including one who experienced a complete response. 

Grade 1 cytokine release syndrome occurred in two patients, and no patients experienced immune effector cell-associated neurotoxicity syndrome. 

The company also announced a $280 million private placement. The proceeds from the private placement, combined with current cash, cash equivalents, short-term investments, and interest receivable, are expected to fund Cullinan’s current operating plan into 2028.

Monday, William Blair initiated coverage on Cullinan with an Outperform rating and a $35-per-share fair value based on the potential of the company’s diversified pipeline of assets, including CLN-619 in endometrial cancer, CLN-978 in B-cell malignancies and autoimmune diseases.

The analyst says the company’s strategy, which is flexible across different treatment methods and emphasizes developing new drugs and licensing existing ones, has led to a diverse portfolio of unique assets. 

This approach consistently offers chances for significant value growth based on clinical results. 

The success of zipalertinib and CLN-619 so far demonstrates the effectiveness of this strategy. With many projects, the company can focus on advancing programs that show promise as standalone treatments.

Price Action: CGEM shares are up 3.75% at $17.70 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CareOfferingsAnalyst RatingsMoversGeneralBriefsExpert IdeasStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!